Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls

S Viskin, R Fish, M Eldar, D Zeltser, M D Lesh, A Glick, B Belhassen

Abstract

Objective—To determine the prevalence of the Brugada sign (right bundle branch block with ST elevation in V1–V3) in idiopathic ventricular fibrillation and in an age matched healthy population.

Design—ECGs from 39 consecutive patients with idiopathic ventricular fibrillation and 592 healthy controls were reviewed. They were classified as definite, questionable, and no Brugada sign (according to predetermined criteria) by four investigators blinded to the subjects’ status.

Results—Eight patients (21%) with idiopathic ventricular fibrillation but none of the 592 controls had a definite Brugada sign (p < 0.005). Thus the estimated 95% confidence limits for the prevalence of a definite Brugada sign among healthy controls was less than 0.5%. A questionable Brugada sign was seen in two patients with idiopathic ventricular fibrillation (5%) but also in five controls (1%) (p < 0.05). Normal ECGs were found following resuscitation and during long term follow up in 31 patients with idiopathic ventricular fibrillation (79%). Patients with idiopathic ventricular fibrillation and a normal ECG and those with the Brugada syndrome were of similar age and had similar spontaneous and inducible arrhythmias. However, the two groups differed in terms of sex, family history, and the incidence of sleep related ventricular fibrillation.

Conclusions—A definite Brugada sign is a specific marker of arrhythmic risk. However, less than obvious ECG abnormalities have little diagnostic value, as a “questionable” Brugada sign was observed in 1% of healthy controls. In this series of consecutive patients with idiopathic ventricular fibrillation, most had normal ECGs.

Keywords: sudden death; cardiac arrest; ventricular fibrillation; Brugada syndrome

In 1987, Belhassen and colleagues reported the first series of patients with idiopathic ventricular fibrillation. The original report included five patients with out of hospital ventricular fibrillation who had no identifiable aetiology and no evidence of heart disease. All these patients had a normal ECG, as well as normal atrioventricular conduction as assessed by invasive electrophysiological studies. Five years later, Brugada and Brugada reported eight patients with idiopathic ventricular fibrillation who had a peculiar ECG, described as “right bundle branch block with ST elevation in V1–V3.” Half of these patients had infranodal conduction delay (HV interval ≥ 60 ms). Since then, more than 100 patients have been identified with aborted sudden death from ventricular fibrillation associated with right bundle branch block and ST elevation, commonly referred to as the Brugada syndrome.

Because idiopathic ventricular fibrillation is a rare disease, the rapidly increasing number of patients with the Brugada syndrome could indicate that the majority of patients with idiopathic ventricular fibrillation have abnormal ECGs. Alternatively, this large number of patients with the Brugada syndrome could represent publication bias or referral bias (that is, increased odds for reporting, or more frequent referral to specialised centres when the Brugada sign is present).

It is important to define the true prevalence of the Brugada sign in idiopathic ventricular fibrillation because it is an easily identifiable ECG abnormality that could be used as a screening tool. Also, patients with idiopathic ventricular fibrillation (with or without the Brugada sign) appear to have unique characteristics that need to be better defined. We therefore reviewed the ECGs of consecutive patients with idiopathic ventricular fibrillation to determine the percentage of those with a Brugada sign. To reduce the odds of biased ECG classification, we included in our blinded review the ECGs of almost 600 controls.

Methods

Patients

We studied 39 consecutive patients with idiopathic ventricular fibrillation referred for evaluation or consultation (24 male, 15 female; mean (SD) age 41 (15) years, range 14 to 69) and 592 controls (346 male, 246 female; age 36 (10) years, range 14 to 67). The diagnosis of idiopathic ventricular fibrillation was in accordance with the criteria of the US idiopathic ventricular fibrillation registry and the European unexplained cardiac arrest registry: first, all the patients had one or more episodes of cardiac arrest with ventricular fibrillation documented at the time of resuscitation; second, all had normal results in the following tests: physical examination, ECG at rest and during exercise stress testing (except for the Brugada sign and the presence of ventricular arrhythmias), normal echocardiogram, and normal cardiac catheterisation with coronary angiography. In addition, the right ventricle...
was visualised by right ventriculography during cardiac catheterisation or by magnetic resonance imaging. Invasive studies were waived in only one patient (a 22 year old man with Brugada sign who had nocturnal ventricular fibrillation and normal non-invasive studies) because he had anoxic brain damage. Patients with cardiac arrest and a normal heart, who could be better classified as suffering from other forms of “polymorphic ventricular arrhythmias in the absence of heart disease” (defined elsewhere) were excluded. Some of our patients appear in previous publications dealing with different aspects of idiopathic ventricular fibrillation.1 8 11–15

The control group consisted of 592 patients referred for electrophysiological evaluation of supraventricular arrhythmias (excluding those with ventricular preexcitation) or referred to one of the surgical services, who fulfilled all the following criteria: age within the age range observed in patients with idiopathic ventricular fibrillation, no history of syncope, no clinical evidence of organic heart disease, and no antiarrhythmic drug treatment.

Coded ECGs of all patients and controls were presented in random order to four experienced cardiologists who were blinded to the patients’ status. Each of the investigators (all familiar with the published illustrations of the Brugada sign) graded the ECGs independently (see below).

ELECTROCARDIOGRAMS

All the ECGs were recorded at standard gain (1 mV/10 mm) and paper speed (25 mm/s). The investigators were requested to grade the traces as showing “definite,” “questionable,” or “no Brugada sign,” according to the following criteria.

Definite Brugada sign—A definite Brugada sign was considered to be present when the 12 lead ECG showed RsR’ and ST elevation in the right precordial leads and looked like the ECGs shown in the publications by Brugada and Brugada.21 6 Accordingly, the investigators (at least three of the four cardiologists) felt that the trace would be “diagnostic of Brugada syndrome” when recorded in a patient with ventricular fibrillation and an apparently normal heart.

Questionable Brugada sign—A questionable Brugada sign was considered to be present when the traces showed QRS abnormalities and ST elevation in the right precordial leads that were of a lesser degree than the abnormalities shown in the figures of the original publications by Brugada and Brugada.1 6 Accordingly, the investigators (at least three of four) felt that these traces would be “consistent with” the Brugada syndrome when present in a patient with ventricular fibrillation and an apparently normal heart.

No Brugada sign—It was considered that the Brugada sign was absent when the ECGs were normal or had minor abnormalities that were not similar to those shown in the figures of the original publications by Brugada and Brugada.2 6

Accordingly, the investigators felt that, with such traces, a diagnosis of Brugada syndrome would not be appropriate, even in a patient with ventricular fibrillation and an apparently normal heart.

We also provided a quantitative description of the abnormalities observed in the right precordial leads (table 1). Finally, as some reports have suggested that the Brugada sign might only become evident during repeated ECG recordings or following administration of class 1A drugs,6 16 we did further ECG recordings in the patients with idiopathic ventricular fibrillation during long term follow up. Selection of these supplementary ECGs was not blinded; they included traces recorded during the administration of class 1A drugs, either intravenously (six patients) or orally (26 patients), and traces showing the most pronounced and the least pronounced ST changes during long term follow up. All the traces in both patients and controls were presented in random order to the grading investigators, who were unaware of the number of traces included for each patient.
Results

PATIENTS WITH IDIOPATHIC VENTRICULAR FIBRILLATION

Six patients with idiopathic ventricular fibrillation had a definite Brugada sign at presentation (fig 2), including three with a definite sign in all follow up traces and three with either a questionable sign or no Brugada sign in the follow up recordings (fig 1). In addition, two patients had a questionable Brugada sign at presentation, but with a definite sign observed at least once during follow up (fig 3). Thus eight patients (21%) with idiopathic ventricular fibrillation (seven male and one female) had the Brugada sign (table 2).

Twenty eight patients with idiopathic ventricular fibrillation had normal ECGs at presentation and three had incomplete right bundle branch block without ST elevation. Thus 31 patients (79%) with idiopathic ventricular fibrillation, aged 14–69 years, had no Brugada sign. None of these had traces graded as showing a “definite” or “questionable” Brugada sign during long term follow up.

Patients with and without a Brugada sign were of similar age at the onset of symptoms (table 2). The ventricular arrhythmias (sponta-
Table 2  Consecutive patients with idiopathic ventricular fibrillation: characteristics of patients with and without a Brugada sign

<table>
<thead>
<tr>
<th></th>
<th>Brugada sign (n=8)</th>
<th>Normal ECG (n=31)</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (mean (SD))</td>
<td>32 (14)</td>
<td>43 (14)</td>
<td>NS</td>
</tr>
<tr>
<td>Male sex</td>
<td>7 (87%)</td>
<td>17 (55%)</td>
<td>NS</td>
</tr>
<tr>
<td>Familial sudden death</td>
<td>2 (25%)</td>
<td></td>
<td>p &lt; 0.05*</td>
</tr>
<tr>
<td>Ventricular fibrillation during sleep</td>
<td>4 (50%)</td>
<td></td>
<td>p &lt; 0.005*</td>
</tr>
<tr>
<td>Inducible ventricular fibrillation</td>
<td>7/7 (100%)†</td>
<td>24 (75%)</td>
<td>NS</td>
</tr>
</tbody>
</table>

*Fisher’s exact test.
†These four patients had additional episodes of ventricular fibrillation (n=3) or syncope (n=1) while awake during daytime.
‡One patient with Brugada sign did not undergo electrophysiological evaluation.

Elevation of the ST segments in leads V1–V2 were commonly seen (table 1), and 1% of the traces of the healthy population were considered to represent a questionable Brugada sign. By study design, none of the controls received antiarrhythmic drugs.

Discussion

The Brugada Sign

An ECG pattern has been described as “right bundle branch block with ST segment elevation,” or as “prominent J waves,” in patients with otherwise idiopathic ventricular fibrillation. Experimental studies suggest that a notch in the action potential is the cellular basis for these J waves. This notch is caused by transient outward (I_{to}) currents, which are more prominent in the right ventricular epicardium. Accordingly, “prominent J waves,” as seen in the Brugada syndrome, could be a marker of unequal spike and dome duration of the action potential in different cardiac regions (epicardium versus endocardium and right versus left ventricle), which identifies patients prone to phase 2 reentrant arrhythmias.

Prevalence of the Brugada Sign

Chen and colleagues estimated that 40–60% of cases of idiopathic ventricular fibrillation are associated with the Brugada syndrome, and these are the figures quoted in contemporary reviews. However, Chen and colleagues based their estimation on “clinical experience” (their sample population was not described); moreover, Brugada and Braguda were coauthors in that study, and it is likely that cardiac arrest survivors with an obvious Brugada sign were specifically referred to those investigators. In other words, referral bias probably increased the percentage of patients with a Brugada sign in that particular series. In contrast, we studied consecutive patients with idiopathic ventricular fibrillation and found a Brugada sign in only 21%.

Previous Studies

Nademanee and colleagues described ECG findings indistinguishable from the Brugada sign in 14 of 17 survivors of cardiac arrest related to the sudden unexplained death syndrome (SUDS) in Thailand. Also, six of 11 similar patients in a Japanese series had the Brugada sign. However, it is not clear if SUDS—an entity that has been known for many years as nocturnal death syndrome in South East Asia—and the Brugada syndromes are one disease, or whether they are different disorders that share a similar ECG pattern. Little is known about the prevalence of the Brugada sign outside South East Asia. For example, three years before the description of the Brugada sign, Martini and colleagues portrayed this ECG appearance in one of six cases with “ventricular fibrillation without heart disease” while “right bundle branch block with ST elevation in V1–V3” was noted in one of 19 patients in a European series of cases of idiopathic ventricular fibrillation.

Data on the prevalence of the Brugada sign in the healthy population are also limited. In their original description, Brugada and Braguda included a control group of patients with right bundle branch block. As in the present study, none of their controls had a Brugada sign. However, because of the small number of controls in that study (only 38 patients), the upper limit of the 95% confidence limits for the prevalence of the Brugada sign in asymptomatic individuals remained high (almost 8%). This upper limit was brought down to less than 0.5% by the large size of our control group in the present study.

Idiopathic Ventricular Fibrillation with and without the Brugada Sign

It is not clear if the Brugada syndrome and “idiopathic ventricular fibrillation with normal ECG” represent different entities. Genetic data are limited for the former and lacking in the latter.

The small number of patients with the Brugada sign in our series limits comparisons between patients with and without this ECG sign. Nevertheless, our observations (table 2) are consistent with published data indicating that both groups have similar age at presentation and similar spontaneous and inducible arrhythmias. On the other hand, the two groups differed with respect to familial involvement, which is relatively common in the Brugada syndrome (a genetic disease) but absent in idiopathic ventricular fibrillation. Finally, the male predominance in the Brugada syndrome is interesting because SUDS—a common form of idiopathic ventricular fibrillation in South East Asia—also affects primarily male patients who have the Brugada sign. It is therefore intriguing that in our series, ventricular fibrillation during sleep (a peculiarity of SUDS) was more common among patients with a Brugada sign. To our knowledge, this is the first reported association of sleep related ventricular fibrillation and the Brugada syndrome in patients not of South East Asian origin.

Limitations

Without genotype analysis, classification of our patients was based exclusively on the ECG. However, the design of our study (which included a large control group and blinded ECG classification) probably reduced our bias toward overdiagnosis. Of more concern is the potential for underdiagnosis of the Brugada sign in our series. The Brugada sign might become evident only during repeated ECGs.
Although we reviewed subsequent ECGs (performed during long term follow up), it was possible that transient ST changes were missed, leading to underestimation of the prevalence of the Brugada sign. Also, the Brugada sign may become apparent following infusion of class 1A or 1C drugs. Intra-venous administration of ajmaline or procainamide did not unmask a Brugada sign in any of our patients with ventricular fibrillation and normal ECGs. However, only six patients (19% of those with idiopathic ventricular fibrillation and a normal ECG) underwent such a challenge. It should be noted, however, that the specificity of ST elevation following class 1 drug administration is not at all clear. This point cannot be overemphasised in view of anecdotal reports suggesting that electrocardiographic features indistinguishable from a Brugada sign may appear in patients without documented or suspected ventricular arrhythmias following administration of class 1C drugs.

CLINICAL IMPLICATIONS

A decade after the description of idiopathic ventricular fibrillation and the Brugada syndrome, it is still impossible to ascertain if these entities are a single disease. We need to define further the similarities (and differences) between “idiopathic ventricular fibrillation with normal ECG”, the Brugada syndrome, and SUDS. An intriguing question is whether quinidine treatment, long advocated by our group for idiopathic ventricular fibrillation, can be beneficial for the Brugada syndrome. Although new evidence suggesting that flecainide administration is a sensitive and specific test for exposing the Brugada sign (among patients carrying genetic mutations for this disease) was recently published by Brugada and colleagues. This new evidence underscores the need for systematic performance of a “flecainide challenge” in patients with idiopathic ventricular fibrillation and apparently normal electrocardiogram, and in patients with questionable symptoms and a questionable Brugada sign.

Apparent induction of ventricular tachycardia after “appropriate pacing” by an implantable dual chamber defibrillator: confusing ICD electrograms

A 38 year old man with a recent large anterior wall myocardial infarction had sustained monomorphic ventricular tachycardia with a rate of 142 beats/min causing palpitations and signs of congestive heart failure. A Biotronik Phylax AV dual chamber defibrillator (ICD) (Biotronik, Berlin, Germany) with a Kainox RV 75 electrode (Biotronik, Berlin, Germany) and a Medtronic model 4568 electrode (Medtronic Inc, Minneapolis, Minneapolis, USA) were implanted.

Two months after implantation he received his first shock. Endocardial electrograms suggested that the episode of ventricular tachycardia was initiated by a paced ventricular complex (the long downward spike in channel 1) following a sudden delay in the AV conduction. The tachycardia was detected by the ICD and antitachycardia pacing was given. The figure shows a stored endocardial electrogram—upper tracing: marker channel (atrial/ventricular); second tracing: atrial intracardiac electrogram; lower tracing: ventricular intracardiac electrogram. Sinus rhythm, cycle length 710 ms, with a sudden delay in the AV node (250 ms), a ventricular paced beat followed by ventricular tachycardia, cycle length 420 ms; A, artefact.

In the tracing an artefact in the lower ventricular electrogram (channel 3) falling before the P wave in the atrial electrogram (channel 2) is observed. As our patient had premature ventricular beats, we hypothesise that this artefact presumably represents a premature ventricular beat with an amplitude that is different from the preceding sinus beats and the beats during ventricular tachycardia. Its timing in the atrial and ventricular electrogram coincides perfectly with the ventricular tachycardia, and what we initially considered as a ventricular paced beat is probably a fusion of the ventricular pacing synchronous with the ventricular tachycardia, without an apparent reset of this tachycardia. Furthermore, it is not uncommon that sustained monomorphic ventricular tachycardia is initiated by beats with another morphology. Whether the electrogram really reflects the signals as recorded by the amplifiers can be discussed, they certainly misled us in our initial interpretation.

DOMINIC THEUNS
GEERT JAN KIMMAN
LUC JORDAESNS
Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls

S Viskin, R Fish, M Eldar, D Zeltser, M D Lesh, A Glick and B Belhassen

Heart 2000 84: 31-36
doi: 10.1136/heart.84.1.31